LD-2 disclosure · 4th Quarter - Report
VIVEX BIOLOGICS
Client
- Name
- VIVEX BIOLOGICS
- Description
- Biologics Company
- Location
- Florida · United States of America
Registrant
- Description
- Consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Education on Human Cellular Tissue Products (HCTPs).
LobbyistsJOHN MCMANUS · ALEX WHALEN
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
LobbyistsJOHN MCMANUS · ALEX WHALEN
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)